Frankfurt Am Main

• Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t … Recruiting
  2024-519479-24-00 4 2025-11-21 metastatic colorectal cancer
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immuno … Recruiting
  2023-507115-35-00 5 2025-11-03 Chronic Immune Thrombocytopenia (ITP)
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting
  2025-520721-21-00 4 2025-10-20 Rheumatoid Arthritis
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17 Hormone receptor positive breast cancer
• A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting
  2024-514974-39-00 5 2025-10-10 Developmental and Epileptic Encephalopathies (DEEs)
• A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting
  2024-519795-11-00 4 2025-10-06 Atopic Dermatitis
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S … Recruiting
  2022-501867-42-01 9 2025-09-08 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting
  2024-516790-78-00 4 2025-09-04 stage IV NSCLC (non-small-cell lung cancer)
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA … Recruiting
  2022-501866-22-00 9 2025-08-26 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• Study to evaluate efficacy and safety of inclisiran in children aged 2 to under 12 years of age with homozygous familial hypercholesterolemi … Recruiting
  2024-514595-41-00 5 2025-08-05 homozygous familial hypercholesterolemia
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting
  2024-515622-80-00 5 2025-06-04 Type 3 Von Willebrand Disease
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 5 2025-05-02 melanoma, cutaneous malignant
• International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting
  2024-515245-42-00 3 2025-04-24 Ewing Sarcoma
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting
  2023-506537-29-00 5 2025-02-24 Haemophilia A
• A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for bipolar depression compared … Recruiting
  2023-506605-19-00 5 2025-02-11 Bipolar depression

Showing 97–120 of 912 trials